Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | CA4 | P22748 | 2/20 | 0.40 |
| ▸ | CA7 | P43166 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | DHODH | Q02127 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MMP1 | P03956 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP9 | P14780 | 1/20 | 0.38 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2548348 | 1.00 | STAT3 (0.43) | STAT3ALDH1A1CA1CA2CA4 | |
| SCHEMBL2548351 | 1.00 | STAT3 (0.43) | STAT3ALDH1A1CA1CA2CA4 | |
| Acetone SCHEMBL9451549 | 0.95 | STAT3 (0.43) | STAT3ALDH1A1CA1CA2CA4 | |
| Acetone SCHEMBL8766802 | 0.95 | STAT3 (0.43) | STAT3ALDH1A1CA1CA2CA4 | |
| Acetone SCHEMBL8568091 | 0.95 | STAT3 (0.43) | STAT3ALDH1A1CA1CA2CA4 | |
| SCHEMBL19067491 | 0.94 | STAT3 (0.39) | STAT3ALDH1A1CA1CA2CA4 | |
| SCHEMBL4343843 | 0.94 | CYP2D6 (0.47) | STAT3ALDH1A1CA1CA2CA4 | |
| SCHEMBL4335282 | 0.94 | CYP2D6 (0.47) | STAT3ALDH1A1CA1CA2CA4 | |
| SCHEMBL140992 | 0.91 | STAT3 (0.46) | STAT3ALDH1A1CA1CA2CA4 | |
| SCHEMBL5471045 | 0.87 | STAT3 (0.43) | STAT3ALDH1A1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117736148-A | Production process of ketoconazole | 盐城凯利药业有限公司 | 2024-03-22 | — | — | CN | claimed |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-10-09 | — | — | US | disclosed |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2025-03-20 | — | — | US | disclosed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| CN-117736148-A | Production process of ketoconazole | 盐城凯利药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-117736148-A | Production process of ketoconazole | 盐城凯利药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | ABBVIE INC (US) | 2023-06-15 | — | — | US | disclosed |
| WO-2022265964-A1 | ORALLY-BIOAVAILABLE NUCLEOSIDE ANALOGS | VenatoRx Pharmaceuticals, Inc. (US) | 2022-12-22 | — | — | WO | disclosed |
| WO-2022216945-A1 | MACROCYCLIC MCL1 INHIBITORS AND USES THEREOF | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-10-13 | — | — | WO | disclosed |
| WO-1992020692-A1 | DI(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | GILEAD SCIENCES, INC. (US) | 1992-11-26 | — | — | WO | disclosed |
| WO-1992020691-A1 | Di(2-PROPYL)ESTERS OF 1-FLUORO-2-PHOSPHONOMETHOXY-3-P-TOLUENESULFONYLOXYPROPANES, THEIR PRODUCING AND UTILIZATION | C^¿ESKOSLOVENSKÁ AKADEMIE VE^¿D (CS) | 1992-11-26 | — | — | WO | disclosed |
| EP-0474250-A2 | Enzymatic process for separating the optical isomers of racemic 1,2-diols | MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENTIFICA E TECNOLOGICA (IT) | 1992-03-11 | — | — | EP | disclosed |
| US-5075309-A | For prevention and treatment of fungal diseases in mammals | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-12-24 | — | — | US | disclosed |
| EP-0402989-A2 | Antifungal 4-[4-[4-[4-[[2-(2,4-difluorophenyl)-2-(1H-azolylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-piperazinyl]phenyl]triazolones and imidazolones | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-12-19 | — | — | EP | disclosed |
| EP-0157623-B1 | OPTICALLY ACTIVE ISOMERS OF BENZOPYRAN DERIVATIVES USEFUL FOR TREATING CARDIOVASCULAR DISEASE | KOWA COMPANY, LTD. (JP) | 1989-03-22 | — | — | EP | disclosed |
| EP-0231444-A2 | Optically active isomers and racemate of 1-(benztriazol-4-yloxy)-3-[2-(2-methoxyphenoxy)-ethylamino]-2-propanol, process for their preparation as well as their use as medicaments | Roche Diagnostics GmbH (DE) | 1987-08-12 | — | — | EP | disclosed |
| US-4678803-A | CARDIOVASCULAR DISORDERS | KOWA COMPANY, LTD. (JP) | 1987-07-07 | — | — | US | disclosed |
| EP-0157623-A2 | Optically active isomers of benzopyran derivatives useful for treating cardiovascular disease | KOWA COMPANY, LTD. (JP) | 1985-10-09 | — | — | EP | disclosed |
| EP-0009075-A1 | Pyridyloxy-propanol amines and esters thereof, process for preparing the same and pharmaceutical compositions containing them | MERCK & CO. INC. (US) | 1980-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | STAT3 1971/4885ALDH1A1 641/4885CA1 4115/4885 |
| US-20230183261-A1 | Macrocyclic MCL-1 Inhibitors and Methods of Use | MCL1, BCL2A1, BCL2L10 | STAT3 1971/4885ALDH1A1 641/4885CA1 4115/4885 |
| US-20250092062-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | STAT3 1971/4885ALDH1A1 641/4885CA1 4115/4885 |
| US-20250313572-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | STAT3 1971/4885ALDH1A1 641/4885CA1 4115/4885 |
| US-20230399340-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | STAT3 1971/4885ALDH1A1 641/4885CA1 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.